Meta-analysis of the positive and Negative Syndrome Scale (PANSS) factor structure

2019 ◽  
Vol 115 ◽  
pp. 113-120 ◽  
Author(s):  
Alan Shafer ◽  
Federico Dazzi
2020 ◽  
Author(s):  
Keane Lim ◽  
Oon-Him Peh ◽  
Zixu Yang ◽  
Gurpreet Rekhi ◽  
Attilio Rapisarda ◽  
...  

Although the Positive and Negative Syndrome Scale (PANSS) is widely utilized in schizophrenia research, variability in specific item loading exist, hindering reproducibility and generalizability of findings across schizophrenia samples. We aim to establish a common metric PANSS factor structure from a large multi-ethnic sample and validate it against a meta-analysis of existing PANSS models. Schizophrenia participants (N = 3511) included in the current study were part of the Singapore Translational and Clinical Research Program (STCRP) and the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE). Exploratory Factor Analysis (EFA) was conducted to identify the factor structure of PANSS and validated with a meta-analysis (N = 16,171) of existing PANSS models. Temporal stability of the PANSS model and generalizability to individuals at ultra-high risk (UHR) of psychosis were evaluated. A five-factor solution best fit the PANSS data. These were the i) Positive, ii) Negative, iii) Cognitive/disorganization, iv) Depression/anxiety and v) Hostility factors. Convergence of PANSS symptom architecture between EFA model and meta-analysis was observed. Modest longitudinal reliability was observed. The schizophrenia derived PANSS factor model fit the UHR population, but not vice versa. We found that two other domains, Social Amotivation (SA) and Diminished Expression (DE), were nested within the negative symptoms factor. Here, we report one of the largest transethnic factorial structures of PANSS symptom domains (N = 19,682). Evidence reported here serves as crucial consolidation of a common metric PANSS that could aid in furthering our understanding of schizophrenia.


2018 ◽  
Vol 11 (4) ◽  
pp. 207-213 ◽  
Author(s):  
Julie Walsh-Messinger ◽  
Daniel Antonius ◽  
Mark Opler ◽  
Nicole Aujero ◽  
Deborah M. Goetz ◽  
...  

2014 ◽  
Vol 36 (4) ◽  
pp. 336-339 ◽  
Author(s):  
Cinthia H. Higuchi ◽  
Bruno Ortiz ◽  
Arthur A. Berberian ◽  
Cristiano Noto ◽  
Quirino Cordeiro ◽  
...  

2018 ◽  
Vol 201 ◽  
pp. 85-90 ◽  
Author(s):  
Zixu Yang ◽  
Keane Lim ◽  
Max Lam ◽  
Richard Keefe ◽  
Jimmy Lee

2012 ◽  
Vol 54 (2) ◽  
pp. 160-165 ◽  
Author(s):  
JOHANNES LANGEVELD ◽  
OLE A. ANDREASSEN ◽  
BJØRN AUESTAD ◽  
ANN FAERDEN ◽  
LARS JOHAN HAUGE ◽  
...  

2000 ◽  
Vol 42 (3) ◽  
pp. 231-239 ◽  
Author(s):  
C Lançon ◽  
P Auquier ◽  
G Nayt ◽  
G Reine

2019 ◽  
Vol 54 (5) ◽  
pp. 453-466 ◽  
Author(s):  
Caitlin OB Yolland ◽  
Donal Hanratty ◽  
Erica Neill ◽  
Susan L Rossell ◽  
Michael Berk ◽  
...  

Objective: There is accumulating evidence that adjunctive treatment with N-acetylcysteine may be effective for schizophrenia. This study aimed to conduct a comprehensive meta-analysis examining the efficacy of randomised control trials investigating N-acetylcysteine as an adjunct treatment for schizophrenia and the first to investigate cognition as an outcome. Methods: We systematically reviewed Medline, EmCare, PsycINFO, Embase, CINAHL Complete, China Knowledge Resource Integrated Database and the Cochrane Clinical Trials online registry for randomised control trials of N-acetylcysteine for schizophrenia. We undertook pairwise meta-analyses of N-acetylcysteine vs placebo for psychosis symptoms and cognition. Results: Seven studies, including n = 220 receiving N-acetylcysteine and n = 220 receiving placebo, met inclusion criteria for the pairwise meta-analyses. Positive and Negative Syndrome Scale negative and total scores were significantly improved in the N-acetylcysteine group after 24 weeks of treatment. The cognitive domain of working memory improved with N-acetylcysteine supplementation. Conclusion: Evidence supports the notion that N-acetylcysteine may be a useful adjunct to standard treatment for the improvement of schizophrenia symptoms, as well as the cognitive domain of working memory. Treatment effects were observed at the later time point (⩾24 weeks), suggesting that longer interventions are required for the success of N-acetylcysteine treatment.


Sign in / Sign up

Export Citation Format

Share Document